Cordyceps Sunshine Biotech Holdings (RAJAF) Accumulated Expenses (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $85074.0 for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 162.49% year-over-year to $85074.0; the TTM figure through Dec 2025 stood at $85074.0 (up 162.49% YoY), while the FY2025 annual figure was $85074.0, up 162.49% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $85074.0, up from $32410.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $85074.0 in Q4 2025, with the low at $26889.0 in Q4 2023.
• The 5-year median for Accumulated Expenses is $56407.0 (2021), against an average of $52706.8.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses slumped 57.15% in 2023, then soared 162.49% in 2025.
• Cordyceps Sunshine Biotech Holdings' Accumulated Expenses stood at $56407.0 in 2021, then climbed by 11.25% to $62754.0 in 2022, then plunged by 57.15% to $26889.0 in 2023, then grew by 20.53% to $32410.0 in 2024, then jumped by 162.49% to $85074.0 in 2025.
• Business Quant data shows RAJAF's Accumulated Expenses at $85074.0 in Q4 2025, $32410.0 in Q4 2024, and $26889.0 in Q4 2023.